Median progression free survival in the selpercatinib group was not reached and was 16.8 months in the cabozantinib/vandetanib group. The Food and Drug Administration ...

Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...

Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) ...

RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...

Results from LIBRETTO-121 showed a confirmed overall response rate of 48% (95% CI, 28-69). The Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the ...

Retevmo was approved for childhood metastatic medullary thyroid, thyroid and solid tumors with RET mutations or gene fusions. The Food and Drug Administration (FDA) granted an accelerated approval to ...

Early prediction of prognosis in advanced solid tumor patients using tumor growth rates with g score in early phase clinical trials.

Medullary thyroid carcinoma (MTC) in MEN2B syndrome is associated with germline RET mutation. Patients harboring de novo mutations are usually diagnosed at more advanced disease stages. We present a ...

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...